Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

NICE Broadens Tumor Profiling Guidance for Early Breast Cancer Adjuvant Chemotherapy in the UK

NextEdge Admin

10 May 2024

2 min 12 sec

The UK’s National Institute for Health and Care Excellence (NICE) has expanded its recommendation for three prognostic gene expression tests to aid in determining adjuvant chemotherapy for a broader group of early breast cancer patients. Myriad Genetics’ EndoPredict(Myriad Genetics recently announced European operations restructuring, selling EndoPredict business to Eurobio Scientific.), Veracyte’s Prosigna, and Exact Sciences’ Oncotype DX are now endorsed for postmenopausal women or men with estrogen receptor-positive, HER2-negative early breast cancer and one to three positive lymph nodes, extending beyond the previous recommendation limited to lymph node-negative patients.

This final guidance, applicable to NHS patients in England and Wales, signifies a significant shift in treatment protocol. However, MammaPrint, Agendia’s breast cancer risk assessment test, did not receive NICE’s endorsement due to concerns regarding its clinical effectiveness and higher costs compared to standard care.

NICE’s independent diagnostic advisory committee made these recommendations based on robust evidence supporting the efficacy of the three endorsed tumor profiling tests. Notably, the companies have agreed to offer these tests to the NHS at a discounted price, ensuring cost-effectiveness.

Mark Chapman, interim director of NICE’s Health Technologies Program, emphasized the committee’s dedication to providing NHS patients with innovative, evidence-based care while prioritizing value for taxpayers’ money. This decision underscores NICE’s commitment to enhancing patient outcomes through the integration of advanced diagnostic technologies into clinical practice.